The Role of Olaratumab in Sarcoma

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in progressive desmoid tumors.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.